Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Patient preferences for treatment of rheumatoid arthritis.

Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR.

Ann Rheum Dis. 2004 Nov;63(11):1372-8.

2.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

3.

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Geborek P, Crnkic M, Petersson IF, Saxne T; South Swedish Arthritis Treatment Group..

Ann Rheum Dis. 2002 Sep;61(9):793-8.

4.

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.

Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW.

J Rheumatol. 2006 May;33(5):854-61.

PMID:
16541481
5.

Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab.

Luong BT, Chong BS, Lowder DM.

Ann Pharmacother. 2000 Jun;34(6):743-60. Review.

PMID:
10860137
6.

Rational use of new and existing disease-modifying agents in rheumatoid arthritis.

Kremer JM.

Ann Intern Med. 2001 Apr 17;134(8):695-706. Review.

PMID:
11304108
8.

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ.

Rheumatology (Oxford). 2007 Nov;46(11):1729-35.

9.

Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM.

Drugs Aging. 2006;23(2):167-78.

PMID:
16536638
11.
12.

Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2004;22(16):1071-95. Review.

PMID:
15524495
13.

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group..

Ann Rheum Dis. 2009 Apr;68(4):519-25. doi: 10.1136/ard.2007.087593.

PMID:
18413440
14.

The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.

van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, Freundlich B, Chang DJ; Etanercept Study 400 Investigators..

Ann Rheum Dis. 2008 Feb;67(2):182-8.

PMID:
17728331
15.

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.

Ann Rheum Dis. 2006 Mar;65(3):328-34.

16.

[Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].

Wallenius M, Rødevand E, Skomsvoll JF.

Tidsskr Nor Laegeforen. 2005 Jun 16;125(12):1664-6. Norwegian.

17.
19.

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.

Choi HK, Seeger JD, Kuntz KM.

J Rheumatol. 2002 Jun;29(6):1156-65.

PMID:
12064828
Items per page

Supplemental Content

Support Center